Year: 2021

Collaboration aims to develop innovative machine learning and artificial intelligence solutions for personalized and earlier treatment in neurology Biogen to gain exclusive rights to TheraPanacea technology in neuroscienceCAMBRIDGE, Mass. and PARIS, Dec. 14, 2021 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) and TheraPanacea today announced that they have entered into a collaboration focused on multiple therapeutic areas in neuroscience, to further build on the companies’ existing relationship. The aim is to leverage machine learning (ML) and artificial intelligence (AI) analysis to develop digital health solutions that may improve patient care, accelerate drug development, and further the understanding of the underlying pathologies of neurological diseases. “We believe that neuroscience is at an inflection point for innovation...

Barry Turkanis Brings Significant Finance, Private Equity, Venture Capital, and Real Estate Experience to AgrifyBarry TurkanisBarry TurkanisBILLERICA, Mass., Dec. 14, 2021 (GLOBE NEWSWIRE) — Agrify Corporation (Nasdaq:AGFY) (“Agrify” or the “Company”), the most innovative and vertically integrated provider of premium cultivation and extraction solutions for the cannabis and hemp industry, today announced the appointment of Barry Turkanis as an independent director on its Board of Directors. Mr. Turkanis replaces Timothy Oakes, who recently resigned from the Board of Directors in order to become the Company’s Chief Financial Officer. Mr. Turkanis will also serve on the Board of Directors’ Audit Committee as well as its Nominating and Corporate Governance Committee. “As we continue to gain momentum and mobilize...

VANCOUVER, British Columbia, Dec. 14, 2021 (GLOBE NEWSWIRE) — Sabre Gold Mines Corp. (TSX:SGLD; OTCQB:SGLDF) (the “Company” or “Sabre Gold”) is pleased to announce a resource update for the Company’s road accessible Brewery Creek Gold Project located in Yukon Territory, Canada. The improved classification of measured and indicated mineral resources increased by 355,000 ounces gold (32%) in all categories and is a result of the Preliminary Economic Assessment (“PEA”) that is nearing completion with results to be provided in January 2022. Giulio T. Bonifacio, President and Chief Executive Officer of Sabre Gold, stated: “We are very pleased with the significant increase in the Measured & Indicated categories of over 350,000 ounces. Sabre Gold intends to further expand gold resources at Brewery Creek in 2022 which will further...

Analysis confirms FCR001 induced durable tolerance in highly mismatched related and unrelated recipients BOSTON and LOUISVILLE, Ky., Dec. 14, 2021 (GLOBE NEWSWIRE) — Talaris Therapeutics, Inc., (Nasdaq: TALS), a late-clinical stage cell therapy company, today presented a new analysis of HLA mismatching between donors and recipients participating in the Company’s Phase 2 trial in living donor kidney transplant (LDKT). High-resolution allele typing at six loci found that FCR001 induced durable immune tolerance in highly mismatched related and unrelated recipients. The findings were shared in an oral presentation by Joseph R. Leventhal, M.D., Ph.D., Fowler McCormick Professor of Surgery at Northwestern University Feinberg School of Medicine and principal investigator for the Phase 2 study, at the American Society of Hematology (ASH)...

BEYOND / HELLO™ Pottsville Will Begin Serving Medical Marijuana Patients in the Schuylkill County Region on December 20th at 10:00 a.m.BEYOND / HELLO™ Pottsville to OpenOn Monday, December 20th at 10:00 a.m., BEYOND / HELLO™ Pottsville will begin serving medical cannabis patients in-store, coupled with the ability to make online reservations through beyond-hello.com for in-store express pickup. BEYOND / HELLO™ Pottsville is conveniently located at 101 N. Centre St., in the old Schuylkill Trust Co. building that will be the only dispensary for 30 minutes in any direction.BEYOND / HELLO™ Pottsville to Carry Wide Variety of Medical Cannabis ProductsBEYOND / HELLO™ Pottsville will give Pennsylvania patients access to Jushi’s suite of high-quality brands, including The Lab, Nira+, and two in-house flower...

Corrected topline Phase 3 ROMAN data demonstrate primary endpoint achieved statistical significance in reducing the incidence of radiotherapy-induced severe oral mucositis (p=0.045) Topline results from single-arm Phase 2a trial of avasopasem in Europe in line with the ROMAN trial results Company plans to discuss avasopasem data with the FDA in 2022 Company to host conference call and live audio webcast on Tuesday, December 14 at 8:30 a.m. ET MALVERN, Pa., Dec. 14, 2021 (GLOBE NEWSWIRE) — Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy (RT) in cancer, today announced that corrected results from its Phase 3 ROMAN trial of avasopasem for the treatment of RT-induced...

Trial met FDA and EMA-pre-specified primary endpoints versus daily standard of care Data to support global regulatory filings in mid-2022 Cidara to host investor conference call today, December 14th, at 8:30 a.m. EST to provide further details on the data SAN DIEGO and CAMBRIDGE, United Kingdom, Dec. 14, 2021 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (NASDAQ: CDTX) and Mundipharma today announced positive topline data from the pivotal ReSTORE Phase 3 clinical trial evaluating the efficacy and safety of its once-weekly antifungal candidate rezafungin as a potential first-line treatment for candidemia and invasive candidiasis. Rezafungin met the primary endpoint for the U.S. Food and Drug Administration (FDA) New Drug Application (NDA) submission of all-cause mortality at Day 30, and also met the primary endpoint for the European...

Thursday, January 13, 2022 at 8:15 am Pacific Time / 11:15 am Eastern Time NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that its President and Chief Executive Officer, Christopher U. Missling, PhD, will present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 8:15 am Pacific Time / 11:15 am Eastern Time at the Westin St. Francis Hotel in San Francisco, CA. A live webcast of the presentation, as well as an archived recording, will be available at...